Glessner Coleen

SEC source: 0001919170-26-000016 · wk-form4_1781118426.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,201

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001919170-26-000012 · wk-form4_1777667327.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 204,219

F1 · deemedExecutionDate: The restricted stock unit grant was approved by the Compensation Committee of Emergent BioSolutions Inc. (the "Company"), on March 2, 2026, subject to stockholder approval of an amendment of the Company's 2006 Stock Incentive Plan (the "Amended Stock Incentive Plan"), under which the restricted stock units were granted. The Company's stockholders approved the Amended Stock Incentive Plan on April 29, 2026.

F2 · shares: Consists of restricted stock units granted under the Company's Amended Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the anniversary of the date of approval, assuming continued service with the Company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001919170-26-000009 · wk-form4_1772762761.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,108

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001919170-26-000009 · wk-form4_1772762761.xml · derivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 294,447

Underlying: Common Stock · 44,834 shares

Expires 2033-03-02

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001919170-26-000006 · wk-form4_1772572600.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,307

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001919170-26-000003 · wk-form4_1770768563.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,620

F2 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001919170-26-000003 · wk-form4_1770768563.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 115,472

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025. On February 06, 2026, the final certification date, the Compensation Committee certified the achievement of the 2023-2025 PSUs at a payout factor of 25% of target resulting in the actual award of 9,615 shares of common stock, which is less than the 38,462 shares previously reported on March 02, 2023 and June 09, 2023.

SEC source: 0001919170-25-000004 · wk-form4_1760646078.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,319

F1 · shares: All transactions listed on this Form 4 were made by the Reporting Person pursuant to a trading plan adopted on December 2, 2024 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

F2 · price: All shares sold at an exact price of $10.00.

SEC source: 0001367644-25-000143 · wk-form4_1749586350.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 174,927

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units.

SEC source: 0001367644-25-000092 · wk-form4_1744238143.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,176

F1 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000047 · wk-form4_1741637831.xml · derivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 249,613

Underlying: Common Stock · 62,500 shares

Expires 2032-03-05

F2 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-25-000047 · wk-form4_1741637831.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 176,656

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three annual installments beginning on the day prior to the anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-25-000034 · wk-form4_1741122483.xml · nonDerivative · entry 3

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,156

F3 · shares: Represents shares of common stock withheld to pay taxes associated with vesting and settlement of restricted stock units

SEC source: 0001367644-25-000034 · wk-form4_1741122483.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,469

F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 24,078 shares previously reported on December 9, 2022.

SEC source: 0001367644-25-000034 · wk-form4_1741122483.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 138,547

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA margin calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. On February 12, 2025, the final certification date, the Compensation Committee certified the achievement of the 2022-2024 PSUs at a payout factor of 0.00% of target resulting in the actual award of 0 shares of common stock, which is below the 5,913 shares previously reported on April 8, 2022.

SEC source: 0001367644-24-000191 · wk-form4_1733864550.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 144,460

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000106 · wk-form4_1718136625.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 163,134

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000049 · wk-form4_1712705251.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,383

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-24-000043 · wk-form4_1710537364.xml · derivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187,113

Underlying: Common Stock · 125,000 shares

Expires 2031-03-12

F1 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-24-000024 · wk-form4_1709595782.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 164,968

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-23-000124 · wk-form4_1686705752.xml · derivative · entry 3

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 62,113

Underlying: Common Stock · 30,770 shares

Expires 2030-06-08

F4 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-23-000124 · wk-form4_1686705752.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,349

F3 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to both cumulative revenues and adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

F2 · balance_after: Represents the corrected number of securities owned due to a computational error in prior Form-4s

SEC source: 0001367644-23-000124 · wk-form4_1686705752.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,579

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company or the day prior to the annual shareholder meeting; whichever is earlier. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

F2 · balance_after: Represents the corrected number of securities owned due to a computational error in prior Form-4s

SEC source: 0001367644-23-000080 · wf-form4_168117008804282.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,154

F1 · shares: Represents shares of common stock withheld to pay taxes.

SEC source: 0001367644-23-000070 · wf-form4_167814940093617.xml · derivative · entry 3

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 31,343

Underlying: Common Stock · 7,692 shares

Expires 2030-03-01

F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

F4 · balance_after: Represents the corrected number of securities owned due to a computational error on prior Form-4.

SEC source: 0001367644-23-000070 · wf-form4_167814940093617.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,674

F2 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2023 and ending December 31, 2025, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

SEC source: 0001367644-23-000070 · wf-form4_167814940093617.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,982

F1 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in two equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-22-000156 · wf-form4_167096997706667.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,136

F2 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in one annual installment beginning on the day prior to the second anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-22-000156 · wf-form4_167096997706667.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,904

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.

SEC source: 0001367644-22-000063 · wf-form4_164979397671420.xml · derivative · entry 3

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,651

Underlying: Common Stock · 23,651 shares

Expires 2029-04-07

F3 · derivative.exercise_date: Vests in three equal installments beginning on the day prior to the anniversary date of the grant.

SEC source: 0001367644-22-000063 · wf-form4_164979397671420.xml · nonDerivative · entry 2

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,826

F2 · shares: Consists of restricted stock units granted under the company's Stock Incentive Plan. These restricted stock units vest in three equal annual installments beginning on the day prior to the first anniversary of the date of grant, assuming continued service with the company. Each restricted stock unit represents the right of the Reporting Person to receive one share of common stock of Emergent BioSolutions Inc., subject to adjustment as provided in the grant agreement.

SEC source: 0001367644-22-000063 · wf-form4_164979397671420.xml · nonDerivative · entry 1

Glessner Coleen · CIK 0001919170 · EVP, Quality & Ethics, and CPL

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,913

F1 · shares: Consists of performance stock units granted under the Emergent BioSolutions Inc. Stock Incentive Plan. Each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted EBITDA as a percentage of total GAAP revenue calculated on a cumulative basis over the three-year period beginning January 1, 2022 and ending December 31, 2024, as certified by the Compensation Committee following the performance period. The amount reported is based on the target performance payout factor, or 100%.